INTRODUCTION

Depression is a chronic debilitating illness affecting approximately 350 million people worldwide annually and imposes a major economic and medical burden on society. The pathology of depression has not been fully elucidated. Research with peripheral blood to find a biomarker for depression has been conducted; however, no objective biomarkers have yet to be found. As a possibility from various studies, abnormalities of synapses and astrocytes are suggested as being involved in the pathology of depression. For example, the reduction in synaptic contacts, the dysregulation of synapse-related gene expression, and glial reduction have been found in several brain regions in depressed patients.1–5 Furthermore, the loss of astrocytes, the most abundant type of glia, is sufficient to induce depressive-like behavior.6 Astrocytes tightly interact with synapses and engage in bidirectional communication critical to the processing of synaptic transmission.
information. Therefore, a dysfunction of astrocytes is to contribute to the synaptic dysfunction present in depression. However, the common pathological molecule between synapse and astrocytes in depression has not yet been found.

Thrombospondin-1 (TSP-1) is a multifunctional extracellular matrix protein. It is rich in platelet alpha granules and was first discovered as a factor secreted by thrombin stimulation. In the peripheral system, several organs such as lung and bone express TSP-1 and have been reported to be important for normal development and maintenance of homeostasis. TSP-1 was also found to be secreted from platelets and other types of cells, such as endothelial cells, monocytes, neutrophils, macrophage, and adipocytes. It has various functions, including coagulation, angiogenesis, wound healing, and immune response. In the central nervous system (CNS), Christopherson et al. reported that TSP-1 is secreted by astrocytes, and promotes synaptogenesis, especially during presynaptic maturation in the developing brain. We previously reported that electroconvulsive seizure (ECS), an animal model of electroconvulsive therapy (ECT), significantly increased TSP-1 mRNA and protein in rat hippocampus via the activation of astrocytes. Together with the above reports of synaptic and astrocytic abnormalities in depression, TSP-1 is suggested as a possible target molecule of depression and its treatment in CNS. In this study, we investigated whether TSP-1 in peripheral blood is possible as a biomarker of depression.

2 | METHODS

2.1 | Subjects

This study was conducted at the Department of Psychiatry of the National Hospital Organization Kure Medical Center between January 2011 and December 2017. Thirty-six patients who were diagnosed according to Diagnostics and Statistical Manual of Mental Disorders (DSM)-IV-TR as major depressive disorder (MDD; 14 male and 22 female) were recruited among inpatients planning to receive ECT based on the guidelines of the American Psychiatric Association. ECT is often prescribed when a patient exhibits episodes of severe major depression, psychosis, and catatonia or has shown insufficient improvement with prescribed pharmacotherapy treatment. Patients with a past or present history of substance abuse, substance dependence, significant neurological illness, or any other significant medical illness were excluded from participation in the current study. After procedures were fully explained, written informed consent was obtained from all subjects to participate in the study. Thirty-six age- and gender-matched serum samples (14 male and 22 female) with no history of past or current psychiatric disorders were picked from among previously collected blood from the healthy subject blood bank owned by the Kure Medical Center, as healthy control subjects. The current study was approved by the Ethics Committee of the National Hospital Organization Kure Medical Center.

2.2 | ECT procedure

ECT was performed according to procedures of a previous report. Anesthesia was induced with thiamylal sodium (2-3 mg/kg, iv) and suxamethonium chloride (0.5-1 mg/kg, iv). The ECT device used was the Thymatron System IV brief pulse square-wave apparatus (Somatics Inc). Because there are many highly urgent and severe cases, electrodes were positioned bilaterally on the frontal-temporal region. Only one adequate seizure was required for each session, which was defined as an electroencephalographic seizure persisting more than 25 seconds with a high amplitude, slow wave, and postictal suppression. The initial stimulus dose was determined using the half-age method. If an adequate electroencephalographic seizure occurred in one session, the same stimulus energy was used in the next session. When a missed or an inadequate seizure occurred, the patient was restimulated with 1.5-2 times the initial stimulus. The maximum number of stimulations for each treatment session was 2. ECT was administered a maximum of three times per week. If any adverse effects (eg, cognitive dysfunction and delirium) occurred, the frequency of the ECT schedule was reduced to once or twice per week. ECT continued until the patient was asymptomatic or the attending psychiatrist determined that the patient had obtained the maximum benefit.

2.3 | Assessment of clinical symptoms

Clinical symptomatic scores were assessed by three trained psychiatrists using the 17-item Hamilton Rating Scale for Depression (HAM-D) prior to the first ECT session (pre-ECT) and after the final ECT session (post-ECT).

2.4 | TSP-1 ELISA

Venous blood samples were taken in the morning (between 7:00 and 8:00 am) at pre-ECT and post-ECT. Blood samples were drawn into anticoagulant-free tubes, kept at room temperature for 30 minutes, and serum was separated by centrifugation at 1500 g for 15 minutes at 4°C. Serum samples were stored at −80°C until assay. Serum TSP-1 levels were measured using TSP-1 ELISA (Quantikine ELISA, R&D Systems) according to the manufacturer’s instructions.

2.5 | Statistical analysis

The data are presented as the mean ± SD or median and interquartile ranges. The normal distribution of data was examined by the Shapiro-Wilk test. Significant differences between two groups were evaluated by using Student’s t test for the normal distribution data or Mann-Whitney U test for the non-normal distribution data. The receiver operating characteristic (ROC) curve for the specificity and the sensitivity of serum TSP-1 was calculated to discriminate
between the MDD and control. The area under the ROC curve (AUC) was calculated for serum TSP-1 as well (AUC = 0.5 indicates no discrimination, and AUC = 1 would indicate a perfect diagnostics test). A Wilcoxon signed-rank test was used to evaluate the statistical differences in the parameters between pre-ECT and post-ECT. The association between various clinical factors of MDD patients, such as gender, age at ECT, age at onset, number of ECT sessions per course, imipramine (IMI)-equivalent dose at pre-ECT, platelet counts, and serum TSP-1 levels, was firstly analyzed by univariate linear regression analysis. Subsequently, multivariate linear regression analysis with stepwise method was conducted in order to correct for confounding factors. The relationship between body mass index (BMI) and serum TSP-1 of all subjects was analyzed using univariate linear regression analysis by gender. Statistical significance was defined as \( P < .05 \). Analyses were performed by using SPSS version 22.0 for Windows (IBM Japan Corporation).

3 | RESULTS

Serum TSP-1 levels of controls and MDD patients were first compared, and there was no statistical difference (control: 18.62 ± 4.65 \( \mu \)g/mL, MDD: 17.12 ± 4.50 \( \mu \)g/mL, \( P = .167 \)). Then, the levels of serum TSP-1 were compared by gender. The serum TSP-1 level was significantly lower in female MDD patients (MDD-F) than female controls (Cont-F). Meanwhile, there was no difference in male MDD patients (MDD-M) and male controls (Cont-M; Figure 1A). In the ROC curve analysis of diagnosis, the AUC of serum TSP-1 in females was 0.678, suggesting that serum levels of TSP-1 may be of low accuracy to diagnose MDD in females.

As shown in Table 1, HAM-D scores were significantly decreased after the course of ECT session, thus indicating that depressive symptoms were significantly improved by ECT. However, no changes in serum TSP-1 levels were observed between pre- and post-ECT (Figure 1B). Consistent with these results, depressive symptoms of pre- and post-ECT were not predictive for serum TSP-1 levels in MDD patients (nonstandardized coefficient \( b = -0.067 \pm 0.048, P = .168 \)).

Subsequently, the influence of clinical factors such as gender, age at ECT, age at onset, the number of ECT sessions per course, IMI-equivalent dose at pre-ECT, and platelet counts was analyzed. First, a univariate linear regression analysis was done with individual clinical factors. Reflecting that platelets are known as the main storage location of TSP-1 in serum, the serum TSP-1 levels were significantly predicted by platelet counts. Age at onset was also a significant predictive factor of serum TSP-1. In addition, gender and IMI-equivalent dose tended to predict serum TSP-1 levels (\( P < .1 \); Table 2). In order to correct for confounding factors, these factors were subsequently analyzed by multivariate linear regression analysis with stepwise method. As a result, platelet counts as well as gender entered the regression model and were revealed as significant predictive factors of serum TSP-1 levels in MDD (Table 3). To summarize these results, the serum TSP-1 levels of MDD patients were not affected only by the platelet counts, and have a gender dependency. In other words, serum TSP-1 is significantly lower in MDD-F than MDD-M after correcting the platelet counts.

There was a significant difference between the IMI-equivalent dose at pre-ECT in MDD-M and MDD-F (Table 1). However, the IMI-equivalent dose at pre-ECT was not extracted as a significant predictive factor as a result of multivariate linear regression analysis (Table 3). Therefore, the doses of antidepressant may not affect the lower serum TSP-1 levels in MDD-F in this study.

A previous study indicated a relationship between BMI and serum TSP-1 specifically in females.\(^1^8\) However, there was no significant difference in BMI between Cont-F and MDD-F (Table 1). Furthermore, BMI did not predict serum TSP-1 levels in females (nonstandardized coefficient \( b = 0.074, P = .71 \)). Therefore, the significant difference in TSP-1 levels in females seen in this study was not attributed to BMI.

4 | DISCUSSION

The main finding of this study is as follows: (a) Serum TSP-1 levels showed a specific decrease in MDD-F, but at an insufficient level for diagnostic ability; (b) serum TSP-1 levels did not change pre- and post-ECT; and (c) serum TSP-1 levels were not correlated with depressive symptoms or doses of antidepressants. In conclusion, serum TSP-1 is a possible female-specific factor that reflects depressive traits, but not state.

We previously reported that chronic ECS increased TSP-1 mRNA and protein in the hippocampus of rats.\(^1^4\) From the perspective of translational research, we expanded to research with human samples. As a preliminary investigation, TSP-1 levels in cerebrospinal fluid (CSF) of several control subjects were tried to investigate. However, CSF TSP-1 levels were less than the detection limit of TSP-1 ELISA (0.944 ng/mL) used in this study. Thus, TSP-1 levels in CSF are expected to be very low. Therefore, the investigation with CSF was thought to be difficult to evaluate TSP-1 levels. Thus, we examined using peripheral blood in this study.

Contrary to the previous results of ECS in rat hippocampus, ECT had no effect on serum TSP-1 levels in humans in the present study. Regarding the discrepancy of these results, the difference in the samples is considered to be greatly affected. In the previous study, the expression of TSP-1 extracted from hippocampal tissue was evaluated, and thus, the changes in the hippocampus could be captured. On the other hand, serum, a component of body fluid, was used in this study. Serum contains a large amount of platelet-derived TSP-1 and might be affected by various peripheral organs that express TSP-1. There is no study showing the relationship between serum TSP-1 levels and CNS TSP-1 levels. Since serum contains TSP-1 not derived from CNS, the alteration by ECT in CNS might not be detectable. In order to analyze the function of TSP-1 in the CNS precisely, further studies are required to analyze the expression in specific brain regions using the brain tissue of a depression model or postmortem human brains.
A previous study indicated a relationship between BMI and serum TSP-1 specifically in females. Serum TSP-1 levels showed a significant positive correlation with BMI in females. Thus, we also investigated whether BMI affected the TSP-1 levels of MDD-F in this study. It revealed that BMI did not affect serum TSP-1 levels. The discrepancy between this study and previous reports may be due to differences in subject characteristics. That is, there were few BMI >25 subjects in this study (3%) compared with the previous study (60%). Therefore, there is a possibility that serum TSP-1 was significantly decreased in MDD-F due to several factors other than BMI. Platelets were also investigated as a potential factor that affects serum TSP-1. However, the multivariate linear regression analysis shows that there seem to be other affecting factors besides platelet counts.

**FIGURE 1**  A, Comparison of serum TSP-1 concentrations between controls and MDD patients separately by gender. Data were shown as the mean ± SD. *P < .05, compared with female controls (Student’s t test). B, Comparison in serum TSP-1 concentrations between pre- and post-ECT separately by gender (Wilcoxon signed-rank test)

Epidemiologically, it has been reported that females are more likely to be depressed at a rate about twice as often as males. Depression which is clinically attributed to estrogen deficiency is often experienced, for example, depression after ovariectomy, postmenopausal, and due to antiestrogen drugs, such as tamoxifen. Taking these things into consideration, it is assumed that female hormones, mainly estrogen, tend to decrease in female depression, and as a result, serum TSP-1 decreases. Although several reports showed that the deficiency or reduction in female hormone increased TSP-1 in various types of tissues, some contrary reports prove the opposite direction. Therefore, there is a possibility that female hormones may have an effect. It is necessary to further investigate the involvement of female hormones and the extent of such effects on serum TSP-1 levels.
This study had some limitations. The sample size was small, and thus, it is desirable to increase the number of subjects, preferably extending to cohort research. All depressed patients in this study are taking medications. Although IMI-equivalent dose was not predictive with TSP-1 levels, it is more desirable to examine in the serum of drug-naive patients. Platelet counts of controls were not obtained because the serum samples were from blood samples already collected at our own biobank. Thus, the comparison between Cont-F and MDD-F was conducted without correcting platelet counts. The value of female hormones was not measured in the samples of this study. Therefore, further study should be considered that includes female hormone levels and platelet counts.

Serum TSP-1 levels were significantly reduced in MDD-F; however, it did not change pre- and post-ECT. The diagnostic ability was

### TABLE 1 Subjects’ demographic data

| Factor                        | Male Control | Male MDD | P-value | Female Control | Female MDD | P-value | Sex difference P-value |
|-------------------------------|--------------|----------|---------|----------------|------------|---------|------------------------|
| Number                        | 14           | 14       | .740b   | 22             | 22         | .913b   | .649                   |
| Age at ECT (y)                | 56.1 ± 12.8  | 57.7 ± 12.0 | .095b  | 59.3 ± 13.6    | 59.8 ± 13.8 | .140b   | .748                   |
| BMI (kg/m²)                   | 23.6 ± 2.6   | 21.5 ± 3.4 | .740    | 22.7 ± 3.1     | 21.1 ± 3.8 | .740    | .740                   |
| Age at onset (y)              | —            | 55.4 ± 13.7 | .740    | —              | 53.6 ± 13.7 | .705    |                        |
| Number of ECT sessions per course | —      | 12.0 [11.0-12.3] | .740 | —             | 10.5 [6.8-12.3] | .740    |                        |
| HAM-D score at pre-ECT        | —            | 21.0 [16.5-32.5] | .740  | —             | 21.0 [17.8-29.0] | .740    |                        |
| HAM-D score at post-ECT       | —            | 4.0 [2.8-7.0]  | .740    | —             | 4.0 [2.5-6.5]    | .740    |                        |
| IMI-equivalent dose at pre-ECT (mg/d) | —        | 136.6 ± 121.3 | .740  | —             | 244.9 ± 172.1   | .740    |                        |
| Platelet counts (×10⁴)        | —            | 23.9 [20.4-27.5] | .740  | —             | 24.2 [21.3-27.0] | .740    |                        |

Notes: Data are shown as the mean ± SD or median [interquartile ranges]. Abbreviations: BMI, body mass index; ECT, electroconvulsive therapy; HAM-D, Hamilton Rating Scale for Depression; IMI, imipramine; MDD, major depressive disorder.

aP-values of comparison between male and female MDD by Student’s t test or Mann-Whitney U test.
bP-values of comparison between control and MDD by Student’s t test.
cP-values of comparison between scores at pre-ECT and those at post-ECT by Wilcoxon signed-rank test.

### TABLE 2 Univariate linear regression analysis of individual factors for serum TSP-1 in MDD

| Factor                        | R²   | Constant | 95% CI     | Nonstandardized coefficient B | 95% CI     | P-value |
|-------------------------------|------|----------|------------|--------------------------------|------------|---------|
| Gender (base: male)           | .101 | 18.881   | 16.532 to 21.231 | -2.890                        | -5.895 to 0.115 | .059    |
| Age at ECT                    | .067 | 22.419   | 15.381 to 29.456 | -0.090                        | -0.207 to -0.027 | .126    |
| Age at onset                   | .160 | 24.319   | 18.393 to 30.245 | -0.133                        | -0.238 to -0.027 | .016*   |
| Number of ECT sessions per course | .042 | 14.289   | 9.330 to 19.248 | 0.271                         | -0.182 to 0.725 | .232    |
| IMI-equivalent dose at pre-ECT (mg/d) | .081 | 18.724   | 16.327 to 21.121 | -0.008                        | -0.017 to -0.001 | .092    |
| Platelet counts (×10⁴)        | .340 | 4.476    | -1.787 to 10.739 | 0.510                         | 0.262 to 0.757 | <.001*  |

Notes: Six variables were selected by stepwise method. R² = .450, model P < .001.

Abbreviations: ECT, electroconvulsive therapy; IMI, imipramine; MDD, major depressive disorder; TSP-1, thrombospondin-1.*P < .05.

### TABLE 3 Multivariate linear regression analysis for serum TSP-1 in MDD

| Factor                        | Nonstandardized coefficient B | 95% CI       | P-value |
|-------------------------------|--------------------------------|--------------|---------|
| Constant                      | 6.153                          | 0.191 to 12.114 | .043*   |
| Gender (base: male)           | -3.013                         | -5.403 to -0.623 | .015*   |
| Platelet counts (×10⁴)        | 0.516                          | 0.287 to 0.746 | <.001*  |

Note: Two variables were selected among six variables by stepwise method. R² = .450, model P < .001.

Abbreviations: MDD, major depressive disorder; TSP-1, thrombospondin-1.*P < .05.
insufficient level. Therefore, serum TSP-1 could not be a diagnosti
c marker for depression. Since serum TSP-1 was consistently re
duced in MDD-F in a state-independent manner, we consider that it is
possible to be a female-specific trait factor of depression. It may
be used as a factor to assess the predisposition of depression in fe-
males. Further investigation is necessary with consideration of the
limitation in this study. Alternatively, serum TSP-1 alone is difficult
to diagnose depression with single biomarker, but it may possible to
determine in the future by combining several biomarkers.

ACKNOWLEDGMENTS
We would like to thank Dr Tsuyoshi Torii (Kure Medical Center and
Chugoku Cancer Center, Japan) for providing CSF samples, and
Professor Junko Tanaka and Tomoyuki Akita (Hiroshima University,
Japan) for advice on statistical analysis. This work was supported in
part by JSPS KAKENHI Grant Numbers JP24790106, JP16K18883,
JP18K07620, JP18K15534, and JP18H02756.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
MOT conducted the experiments, analyzed the results, and wrote
the initial draft of the manuscript. WO, KI, and CS collected the sam-
ples. NK and WO performed the experimental support, analyzed the
data, and prepared the figure and tables. All authors contributed to
the discussion. MT designed the experiments and revised the manu-
script. All authors reviewed the results and approved the final ver-
sion of the manuscript.

DATA REPOSITORY
We agree to deposit the data and publish part of it as supporting
information.

APPROVAL OF THE RESEARCH PROTOCOL BY AN
INSTITUTIONAL REVIEWER BOARD
The protocol for this research project has been approved by a
suitably constituted Ethics Committee of the National Hospital
Organization Kure Medical Center (Approval No. 26-52, 27-09).

INFORMED CONSENT
All informed consent was obtained from the subjects to participate
in the study.

ORCID
Minoru Takebayashi https://orcid.org/0000-0001-9962-8444

REFERENCES
1. Kang HJ, Voleti B, Hajszen T, Rajkowska G, Stockmeier CA, Licznerski
P, et al. Decreased expression of synapse-related genes and loss of
synapses in major depressive disorder. Nat Med. 2012;18(9):1413–7.
2. Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC, et al. Altered expression of synapse and glutamate
related genes in post-mortem hippocampus of depressed subjects.
Int J Neuropsychopharmacol. 2013;16(1):69–82.
3. Ongür D, Drevets WC, Price JL. Glial reduction in the subgen-
ual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA.
1998;95(22):13290–5.
4. Rajkowska G, Miguel-Hidalgo JI. Gliogenesis and glial pathology
in depression. CNS Neurol Disord Drug Targets. 2007;6(3):
219–33.
5. Takebayashi M, Hisaoka K, Tsuchioka M. Glial dysfunction in mood
disorders: the role of GDNF. In: Shirayama Y, Chaki S, editors.
Recent developments on depression research. Kerala: Research
Signpost, 2009; p. 125–43.
6. Banasr M, Duman RS. Glial loss in the prefrontal cortex is suf-
ficient to induce depressive-like behaviors. Biol Psychiatry.
2008;64(10):863–70.
7. Rial D, Lemos C, Pinheiro H, Duarte JM, Gonçalves FQ, Real JI,
et al. Depression as a glial-based synaptic dysfunction. Front Cell
Neurosci. 2015;9:521.
8. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn
H, et al. Thrombospondin-1 is required for normal murine pulmo-
nary homeostasis and its absence causes pneumonia. J Clin Invest.
1998;101(5):982–92.
9. Baenziger NL, Brodie GN, Majerus PW. Isolation and properties
of a thrombin-sensitive protein of human platelets. J Biol Chem.
1972;247(9):2723–31.
10. Mosher DF, Doyle MJ, Jaffe EA. Synthesis and secretion of
thrombospondin by cultured human endothelial cells. J Cell Biol.
1982;93(2):343–8.
11. Varma V, Yao-Borengasser A, Bodles AM, Rasouli N, Phanavan B,
Nolen GT, et al. Thrombospondin-1 is an adipokine associated with
obesity, adipose inflammation, and insulin resistance. Diabetes.
2008;57(2):432–9.
12. Adams JC, Lawler J. The thrombospondins. Cold Spring Harb
Perspect Biol. 2011;3(10):a009712.
13. Christopherson KS, Ullian EM, Stokes CCA, Mullowney CE, Hejl JW,
Agah A, et al. Thrombospondins are astrocyte-secreted proteins
that promote CNS synaptogenesis. Cell. 2005;120(3):421–33.
14. Okada-Tsuchioka M, Segawa M, Kajitani N, Hisaoka-Nakashima
K, Shibasaki C, Morinobu S, et al. Electroconvulsive seizure in-
duces thrombospondin-1 in the adult rat hippocampus. Prog
Neuropsychopharmacol Biol Psychiatry. 2014;48:236–44.
15. American Psychiatric Association, editor. The practice of elec-
troconvulsive therapy: recommendations for treatment, training,
and privileging: (A task force report of the American Psychiatric
Association). 2nd ed. Washington, DC: American Psychiatric Press;
2001.
16. Shibasaki C, Takebayashi M, Fujita Y, Yamawaki S. Factors asso-
ciated with the risk of relapse in schizophrenic patients after a
response to electroconvulsive therapy: a retrospective study.
Neuropsychiatr Dis Treat. 2015;11:67–73.
17. Petrides G, Fink M. The, “half-age” stimulation strategy for ECT
dosing. Convuls Ther. 1996;12(3):138–46.
18. Matsuo Y, Tanaka M, Yamakage H, Sasaki Y, Muranaka K, Hata H,
et al. Thrombospondin 1 as a novel biological marker of obesity and
metabolic syndrome. Metabolism. 2015;64(11):1490–9.
19. Seeman MV. Psychopathology in women and men: focus on female
hormones. Am J Psychiatry. 1997;154(12):1641–7.
20. Tan XJ, Lang JH, Zheng WM, Leng JH, Zhu L. Ovarian steroid hor-
mones differentially regulate thrombospondin-1 expression in cul-
tured endometrial stromal cells: implications for endometriosis.
Fertil Steril. 2010;93(1):328–31.
21. Bonagura TW, Aberdeen GW, Babischkin JS, Koos RD, Pepe GJ,
Albright ED. Divergent regulation of angiopoietin-1 and -2, Tie-2,
and thrombospondin-1 expression by estrogen in the baboon endo-
metrium. Mol Reprod Dev. 2010;77(5):430–8.
22. Tanaka M, Kanazashi M, Maezawa T, Kondo H, Fujino H. Abnormalities in three-dimensional capillary architecture and imbalance between vascular endothelial growth factor-A and thrombospondin-1 in soleus muscle of ovariectomized rat. Acta Histochem. 2015;117(7):605–11.

23. Hyder SM, Liang Y, Wu J. Estrogen regulation of thrombospondin-1 in human breast cancer cells. Int J Cancer. 2009;125(5):1045–53.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.